Original Article

Tuberculosis and associated risk factors among children and adolescent population in Serbia: 12 year’s retrospective study

Maja B Stosic¹, Lidija Sagic², Danijela Simic¹, Verica Jovanovic¹, Violeta Rakic¹, Tatjana Adzic Vukicevic³

¹ Institute of Public Health of Serbia “Dr Milan Jovanovic Batut”, Belgrade, Serbia
² Municipality Institute for Lung Diseases and Tuberculosis, Belgrade, Serbia
³ University Clinic for Pulmonology, Clinical Center of Serbia, Belgrade, Serbia

Abstract

Introduction: Recognition and epidemiological control of childhood and adolescent tuberculosis (TB) is essential to achieve effective control of TB in general as it presents high risk for transmission in the community. The aim of the study is to provide a descriptive and analytic overview of the trends in childhood and adolescent TB notifications and treatment outcomes and to identify factors associated with treatment success in a twelve-year period in Serbia.

Methodology: We performed a retrospective trend analysis and analysis of treatment outcomes of 596 child and adolescent TB cases notified in Serbia in the period 2005–2016 from all health facilities, as well as logistic regression analysis to identify predictors of treatment success.

Results: Factors independently associated with treatment success were: new TB (OR=2.60; 95% CI: 1.45–3.74), male sex (OR=2.55; 95% CI: 2.09–3.00), pulmonary TB (OR=3.34; 95% CI: 2.34–4.34), comorbidities (OR=2.58; 95% CI: 2.24–2.91), age below 5 years (OR=0.37; 95% CI: 0.32–0.43), and social vulnerability (OR=0.40; 95% CI: 0.34–0.46).

Conclusions: In order to improve TB treatment outcomes among children and adolescent population in Serbia, it is important to focus on female, age group 5-18, EPTB, retreatment cases and socially vulnerable groups.

Key words: tuberculosis; children; adolescents; risk factors; Serbia.

J Infect Dev Ctries 2021; 15(6):818-825. doi:10.3855/jidc.14451

(Received 03 December 2020 – Accepted 09 February 2021)

Copyright © 2021 Stosic et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Even in the twenty-first century, tuberculosis (TB) remains the one of the main causes of morbidity and mortality worldwide. There were an estimated 1.1 million new cases of childhood TB and an estimated 205,000 TB deaths in children in 2018 [1,2]. Tuberculosis in children is often under-diagnosed as they experience a variety of symptoms and therefore are a particularly vulnerable population. In early childhood, immature immune systems make children more susceptible to develop severe disseminated forms of the disease, such as TB meningitis, miliary TB, and TB of the bones and joints [3]. Moreover, conventional diagnostic tests, such as sputum smear microscopy and culture, have low sensitivity in children due to difficulties in obtaining adequate samples [4]. Challenges in microbiological confirmation and clinical diagnosis in children often lead to missing cases, delayed and ineffective treatment, disease progression and increased risk of death [5]. In addition, social determinants and underlying factors, such as overcrowding, malnutrition and poverty contribute to childhood TB in the communities [6]. Previous studies identified that risk factors for negative treatment outcomes in children with TB include HIV positivity [7,8], age below 5 years [7,9], low body weight [10], and smear positivity of the source of infection [11]. In the period 2005–2016, TB notification rate in Serbia decreased from 32 per 100,000 in 2005 to 11 per 100,000 in 2016. The proportion of TB cases among children under 14 years of age was 1% [12]. An in-depth analysis of notification and treatment outcomes of childhood TB has not been undertaken before in Serbia. Previous studies in Serbia have focused on trends in TB incidence and mortality among children and highlighted the need to further describe the trends to improve our understanding of the TB burden and performance of the TB control programme [13]. This analysis aims to provide a descriptive and analytic overview of the trends in childhood and adolescent TB notifications and treatment outcomes and to identify factors associated with treatment success in a twelve-year period in Serbia.
Methodology

Source population

Within the descriptive study design, we performed trend analysis of case notifications and analysis of treatment outcomes of all TB cases (child and adolescent) diagnosed in the period 2005–2016 from all health facilities in Serbia, based on the data derived from the national electronic data collection system for TB of the Ministry of Health and Institute of Public Health of Serbia. We analyzed notified child and adolescent TB cases by age, sex, bacteriological confirmation, anatomical site of the disease, history of previous treatment, risk factors (such as: being contact with confirmed TB case, having comorbidities and social vulnerability defined as potential harm to people involving combination of factors that determine the degree to which someone's life and livelihood are put at risk by a discrete and identifiable event in nature or in society), HIV status (recorded since 2010), multidrug resistance and bacille Calmette-Guerin (BCG) vaccination coverage. Internal consistency of the data was analyzed using WHO checklists [14,15]. Treatment results included: cured, treatment completed, defaulting (lost to follow-up), died, failed and not evaluated [16,17]. TB diagnosis and case definitions were used from the National guidelines for TB control in Serbia developed in line with WHO guidelines [18].

Diagnosis

TB diagnosis in children was based on clinical and radiological findings and was confirmed bacteriologically and/or histologically. Laboratory confirmation was performed by detection of *Mycobacterium tuberculosis* complex from a clinical specimen, either by culture or by a newer molecular technique [18].

Case definition and classification

Pulmonary tuberculosis (PTB) refers to any bacteriologically confirmed or clinically diagnosed case of TB involving the lung parenchyma or the tracheobronchial tree. PTB also includes cases that affect the lung with additional extra-pulmonary manifestations. Extra-pulmonary tuberculosis (EPTB) refers to any bacteriologically confirmed or clinically diagnosed case of TB involving organs other than the lungs, e.g. pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones or meninges. New patients are defined as those who have never been treated for TB or have taken anti-TB drugs for less than one month. Previously treated patients are defined as those who have received 1 month or more of anti-TB treatment. Multidrug resistance (MDR) refers to resistance to at least isoniazid and rifampicin together. Treatment outcomes were categorized according to the latest WHO definitions and reporting framework for tuberculosis [15].

Statistical analysis

Analyses of trends of TB notification rates and treatment outcomes during the 12-year study period were performed for all cases. National Statistical Office

Table 1. Demographic characteristics of child and adolescent TB cases notified in Serbia 2005-2016.

| Characteristics | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | Total (N) |
|-----------------|------|------|------|------|------|------|------|------|------|------|------|------|----------|
| Number of cases | 60   | 63   | 64   | 58   | 65   | 52   | 39   | 53   | 47   | 44   | 21   | 30   | 596      |
| Notification rate (per 100,000) | 3.7  | 3.7  | 3.8  | 3.8  | 3.9  | 3.9  | 4.0  | 4.2  | 4.2  | 4.3  | 4.3  | 4.4  |          |
| Gender | | | | | | | | | | | | | |
| Male | 25   | 30   | 38   | 25   | 36   | 25   | 16   | 29   | 18   | 23   | 14   | 15   | 294      |
| Female | 41.7 | 47.6 | 59.4 | 43.1 | 55.4 | 48.1 | 41.0 | 54.7 | 38.3 | 52.3 | 66.7 | 50.0 |          |
| Age category | | | | | | | | | | | | | |
| 0 to 4 | 35   | 33   | 26   | 33   | 29   | 27   | 23   | 24   | 29   | 21   | 7    | 15   | 302      |
| 5 to 14 | 58.3 | 52.4 | 40.6 | 56.9 | 44.6 | 51.9 | 59.0 | 45.3 | 61.7 | 47.7 | 33.3 | 50.0 |          |
| Notification rate (per 100,000) | 2.3  | 2.7  | 3.1  | 2.7  | 3.1  | 1.2  | 2.5  | 1.7  | 0.4  | 2.2  | 1.3  | 0.0  |          |
| 15-18 | 14   | 17   | 21   | 15   | 13   | 14   | 7    | 14   | 13   | 16   | 5    | 0    | 149      |
| Notification rate (per 100,000) | 23.3 | 27.0 | 32.8 | 25.9 | 20.0 | 26.9 | 17.9 | 26.4 | 27.7 | 36.4 | 23.8 | 0.0  |          |
| TB: tuberculosis.
provided population data for each year [18]. Trends were analyzed for case notification by age, sex, bacteriological confirmation, anatomical site of the disease, history of previous treatment, risk factors (such as being contact with confirmed TB case, having comorbidities and social vulnerability), HIV status (recorded since 2010), multidrug-resistance and BCG vaccination coverage. To identify factors associated with treatment success we used a logistic regression analysis. The variables age, sex, bacteriological confirmation, anatomical site of the disease, history of previous treatment, contact with confirmed TB case, comorbidities, social vulnerability, HIV status, multidrug resistance and BCG vaccination coverage were entered in univariate logistic regression analysis (ULRA) model. The outcome of the model was dichotomized as treatment success (cured or completed) vs negative treatment outcome (failed, died, lost to follow-up or not evaluated).

The variables that showed statistically significant association at \( p \) value \( \leq 0.05 \) in ULRA were entered in multivariable logistic regression analysis (MLRA) models. Statistical Package for Social Sciences (IBM SPSS) version 24 was used for data analysis and \( p \) values \( \leq 0.05 \) were considered statistically significant.

**Ethics statement**

This analysis used routine comprehensive surveillance data collected programmatically, no one provided informed consent. All data were completely de-identified prior to the analysis. Review Board (RB) of the Institute of Public Health of Serbia determined the study exempt from ongoing review and waived the requirement for informed consent.

**Results**

**Characteristics of the cases**

There were almost the same representatives from both genders (male to female ratio = 0.97:1). The most patients belonged to the age group 15-18 years (389, 65.3%) (Table 1).

Most of the cases, (473, 79.4%) had PTB. A total of 583 cases (97.8%) were new. Among all 305 (51.2%) cases were bacteriologically confirmed whereas 60% (N = 284) were PTB cases and 17.1% (N = 21) EPTB cases. MDR TB was notified and recorded in 3 out of 225 cases (37.8%) covered by drug-susceptibility testing (DST). HIV status has been recorded in TB register since 2010. From 2010 to 2016, there were no HIV positive cases among 12 (4.2%) TB cases tested, while for 274 cases (95.8%) HIV status was unknown. Social vulnerability was notified in 85 (14.3%) and comorbidities in 13 (2.2%) cases. Over the observed period, BCG vaccination coverage ranged from 98-99% (Table 2).

**Trends analysis of tuberculosis case notifications among child and adolescent population**

Between 2005 and 2016 the proportion of child and adolescent cases among all TB cases significantly increased from 2.5% in 2005 to 4.0% in 2016 (\( p \) value for trend < 0.05). Bacteriological confirmation of cases significantly increased during the observed period, from 46.6% in 2005 to 73.3% in 2016 (\( p \) value for trend < 0.05). The proportions of PTB increased significantly from 71.7% in 2005 to 96.7% in 2016, while EPTB decreased over time (\( p \) value for trend < 0.05). Social vulnerability of cases significantly increased during the observed period, from 8.3% in 2005 to 33.3% in 2016 (\( p \) value for trend < 0.05). There was a significant decrease in unknown DST results from 86.7% in 2005 to 40.0% in 2016 (\( p \) value for trend < 0.05). The proportions of HIV testing results increased significantly (\( p \) value for trend < 0.05), from 0.0% in 2010 to 10.0% in 2016.

**Trends in tuberculosis treatment outcomes among child and adolescent population**

Treatment outcome was available for all 596 cases. Treatment success significantly increased among retreatment cases (\( p \) value for trend < 0.05), from 0% in 2005 to 100% in 2016. The proportion of patients lost to follow-up decreased significantly among PTB cases, from 11.6% in 2005 to 3.5% in 2016 and among previously treated cases from 50.0% in 2005 to 0.0% in 2016 (\( p \) value for trend < 0.05). The proportion of child and adolescent TB patients’ deaths remained stable over time at the level of zero to one death per year (\( p \) value for trend > 0.05) (Table 4).

**Factors associated with treatment outcomes**

In the multivariable logistic regression analysis (Table 3), factors independently associated with treatment success were: new TB (OR = 2.60; 95% CI: 1.45–3.74), male sex (OR = 2.55; 95% CI: 2.09–3.00), pulmonary TB (OR = 3.34; 95% CI: 2.34–4.34), and comorbidities (OR = 2.58; 95% CI: 2.24–2.91). Factors independently associated with negative treatment outcomes were age below 5 years (OR = 0.37; 95% CI: 0.32–0.43), and social vulnerability (OR = 0.40; 95% CI: 0.34–0.46).
Table 2. Clinical and microbiological characteristics of cases of child and adolescent TB notified in Serbia 2005-2016.

| Characteristics                          | Year | N (%)    | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | Total (N) |
|------------------------------------------|------|----------|------|------|------|------|------|------|------|------|------|------|------|------|----------|
| **Bacteriological confirmation (%)**     |      | 46.7     | 55.6 | 35.9 | 60.3 | 44.6 | 55.8 | 53.8 | 52.8 | 55.3 | 50.0 | 33.3 | 73.3 |        |
| **Anatomic site of the disease**         |      |          |      |      |      |      |      |      |      |      |      |      |      |      |          |
| PTB                                      |      | 43       | 47   | 49   | 49   | 50   | 40   | 31   | 43   | 39   | 35   | 18   | 29   | 473   |
| EPTB                                     |      | 71.7     | 74.6 | 76.6 | 84.5 | 76.9 | 76.9 | 79.5 | 81.1 | 83.0 | 79.5 | 85.7 | 96.7 |        |
| **EPTB localization**                    |      | 17       | 16   | 15   | 9    | 15   | 12   | 8    | 10   | 8    | 9    | 3    | 1    | 123   |
| Pleura                                   |      | 28.3     | 25.4 | 23.4 | 15.5 | 23.1 | 23.1 | 20.5 | 18.9 | 17.0 | 20.5 | 14.3 | 3.3  |        |
| **History of previous treatment**        |      |          |      |      |      |      |      |      |      |      |      |      |      |      |          |
| New                                      |      | 58       | 62   | 63   | 58   | 64   | 52   | 39   | 52   | 44   | 43   | 19   | 29   | 583   |
| Previously treated                       |      | 96.7     | 98.4 | 98.4 | 100.0| 98.5 | 100.0| 100.0| 98.1 | 93.6 | 97.7 | 90.5 | 96.7 |        |
| **Risk groups**                          |      | 2        | 1    | 1    | 1    | 0    | 1    | 1    | 1    | 1    | 2    | 1    | 0    | 11    |
| Contacts                                 |      | 38.3     | 23.8 | 35.9 | 29.3 | 33.8 | 30.8 | 30.8 | 43.4 | 36.2 | 40.9 | 42.9 | 20.0 |        |
| Co-morbidity (immunosuppression)         |      | 0        | 2    | 1    | 0    | 0    | 2    | 1    | 3    | 3    | 1    | 0    | 0    | 13    |
| Social vulnerability                     |      | 5.0      | 8    | 13   | 9    | 7    | 8    | 2    | 4    | 10   | 0    | 10   | 85    |
| **HIV status**                           |      | 8.3      | 12.7 | 20.3 | 15.5 | 13.8 | 13.5 | 20.5 | 3.8  | 8.5  | 22.7 | 0    | 33.3  |        |
| Positive                                 |      | 0        | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0     |
| Negative                                 |      | 0        | 1    | 2    | 3    | 1    | 3    | 1    | 3    | 12   | 0    | 4.5  | 8.0  |        |
| Unknown                                  |      | 52       | 38   | 51   | 44   | 42   | 42   | 20   | 27   | 274  | 100.0| 97.4 | 96.2 | 93.6 | 95.5  |
| **Multidrug resistance**                 |      | 13.3     | 17.5 | 21.9 | 39.7 | 56.9 | 57.7 | 41.0 | 45.3 | 44.7 | 34.1 | 23.8 | 60.0 |        |
| No                                       |      | 8        | 11   | 14   | 23   | 37   | 30   | 16   | 24   | 21   | 15   | 5    | 18   | 222   |
| Yes                                      |      | 0        | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 2    | 0    | 0    | 3    |        |
| Unknown                                  |      | 52       | 52   | 50   | 35   | 37   | 22   | 23   | 29   | 26   | 27   | 16   | 12   | 371   |
| BCG vaccination coverage (%)             |      | 86.7     | 82.5 | 78.1 | 60.3 | 56.9 | 42.3 | 59.0 | 54.7 | 55.3 | 61.4 | 76.2 | 40.0 |        |

TB: tuberculosis; PTB: pulmonary TB; EPTB: extra-pulmonary TB; BCG: bacillus Calmette-Guerin. 1Data on HIV status are available in TB register from 2010.
Table 3. Treatment outcomes of child and adolescent tuberculosis cases in Serbia, 2005-2016.

| Treatment outcome | Year | N (%) | Year | N (%) | Year | N (%) | Year | N (%) | Year | N (%) | Year | N (%) | Year | N (%) | Year | N (%) | Year | N (%) | Year | N (%) | Year | N (%) | Total (N) |
|-------------------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|----------|
| **New cases**     |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |          |
| PTB1              |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |          |
| Cured + Completed | 37   | 42    | 48   | 45    | 43   | 39    | 29   | 39    | 35   | 32    | 17   | 28    | 434  |       |      |      |      |      |      |      |      |      |          |
| | 86.05 | 89.36 | 97.96| 91.84 | 86.00| 97.50 | 93.55| 90.70 | 89.74| 91.43 | 94.44| 96.55|       |      |      |      |      |      |      |      |      |      |          |
| **Negative outcomes** | 6    | 5     | 1    | 4     | 7    | 1     | 2    | 4     | 3    | 1     | 1    |       |      |      |      |      |      |      |      |      |          |
| | 13.95 | 10.64 | 2.04 | 8.16  | 14.00| 2.50  | 6.45 | 9.30  | 10.26| 8.57  | 5.56 | 3.45 |       |      |      |      |      |      |      |      |      |          |
| **Total**         | 43   | 47    | 49   | 49    | 50   | 40    | 31   | 43    | 39   | 35    | 18   | 29    | 473  |       |      |      |      |      |      |      |      |      |          |
| **EPTB2**         |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |          |
| Cured + Completed | 17   | 16    | 13   | 9     | 15   | 11    | 8    | 10    | 7    | 9     | 3    | 1     | 119  |       |      |      |      |      |      |      |      |      |          |
| | 100.00| 100.00| 86.67| 100.00| 100.00| 100.00| 100.00| 100.00| 87.50| 100.00| 100.00| 100.00|       |      |      |      |      |      |      |      |      |          |
| **Negative outcomes** | 0    | 0     | 2    | 0     | 0    | 1     | 0    | 1     | 0    | 0     | 0    | 0     | 0    |       |      |      |      |      |      |      |      |      |          |
| | 0.00  | 0.00  | 13.33| 0.00  | 0.00  | 8.33  | 0.00 | 12.50 | 0.00 | 0.00  | 0.00 | 0.00  |      |      |      |      |      |      |      |      |      |          |
| **Total**         | 17   | 16    | 15   | 9     | 15   | 12    | 8    | 10    | 8    | 9     | 3    | 1     | 123  |       |      |      |      |      |      |      |      |      |          |
| **All new TB cases** |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |          |
| Cured + Completed | 54   | 56    | 60   | 54    | 60   | 50    | 37   | 49    | 40   | 40    | 17   | 28    | 545  |       |      |      |      |      |      |      |      |      |          |
| | 93.10 | 90.32 | 95.24| 93.10 | 93.75| 96.15 | 94.87| 94.23 | 90.91| 93.02 | 89.47| 96.55|       |      |      |      |      |      |      |      |      |          |
| **Negative outcomes** | 4    | 6     | 3    | 4     | 4    | 2     | 2    | 3     | 4    | 3     | 2    | 1     | 1    |       |      |      |      |      |      |      |      |      |          |
| | 6.90  | 9.68  | 4.76 | 6.90  | 6.25 | 3.85  | 5.13 | 5.77  | 9.09 | 6.98  | 10.53| 3.45 |       |      |      |      |      |      |      |      |      |          |
| **Total**         | 58   | 62    | 63   | 58    | 64   | 52    | 39   | 52    | 44   | 43    | 19   | 29    | 583  |       |      |      |      |      |      |      |      |      |          |
| **Previously treated cases** |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |          |
| Cured + Completed | 0    | 0     | 1    | 0     | 0    | 0     | 1    | 2     | 1    | 1     | 1    | 1     | 7    |       |      |      |      |      |      |      |      |      |          |
| | 0.00  | 0.00  | 100.00| 0.00  | 0.00  | 0.00  | 100.00| 0.00  | 100.00| 66.67 | 100.00| 50.00 | 100.00|       |      |      |      |      |      |      |      |      |          |
| **Negative outcomes** | 2    | 1     | 0    | 0     | 1    | 0     | 0    | 1     | 0    | 1     | 0    | 0     |      |       |      |      |      |      |      |      |      |      |          |
| | 100.00| 100.00| 0.00  | 0.00  | 0.00  | 0.00  | 0.00  | 0.00  | 33.33 | 0.00  | 50.00 | 0.00  |      |      |      |      |      |      |      |      |      |          |
| **Total**         | 2    | 1     | 1    | 0     | 0    | 0     | 1    | 3     | 1    | 2     | 1    | 13    |      |       |      |      |      |      |      |      |      |          |

**Table 4. Factors associated with treatment success among notified child and adolescent TB cases in Serbia. 2005-2016 according to the multivariable logistic regression analysis.**

| Characteristics | Treatment success | OR (95% CI) | P-value |
|-----------------|-------------------|-------------|---------|
| **Gender**      |                   |             |         |
| Male            |                   | 2.55 (2.09-3.00) | 0.000   |
| Female          |                   |             |         |
| **Age category**|                   |             |         |
| 0-4             |                   | 0.37(0.32-0.43) | 0.000   |
| 5 to 18         |                   |             |         |
| **TB localization** |               |             |         |
| PTB1            |                   | 3.34 (2.34-4.34) | 0.000   |
| EPTB2           |                   |             |         |
| **Registration category** |             |             |         |
| New             |                   | 2.60 (1.45-3.74) | 0.000   |
| Retreatment     |                   |             |         |
| **Comorbidities** |                 |             |         |
| Yes             |                   | 2.58 (2.24-2.91) | 0.000   |
| Social vulnerability |             |             |         |
| Yes             |                   | 0.40 (0.34-0.46) | 0.000   |

**TB: tuberculosis; PTB: pulmonary TB; EPTB: extra-pulmonary TB.**
Discussion

Over the twelve-year study period, we found a stable trend in child and adolescent TB notification rate, while significantly increasing trend of proportions of child and adolescent cases among all TB cases. These proportions correspond to EU/EEA surveillance data [2], less than proportions presented in WHO standards and benchmarks for childhood TB (5–15%) for middle-income countries where Serbia belongs [19], reflecting some improvements in case detection. However, it is reasonable to assume that country is still facing challenges in TB control in child and adolescent population such as: sub-registration [20], under diagnosis and misdiagnosis due to difficulties in obtaining adequate samples, especially in children aged <5 years, as illustrated by a recent review where between 1% and 23% of pneumonia cases also had TB [23,24].

We found that the proportions of bacteriological confirmation of cases and drug susceptibility testing significantly increased during the observed period. It might be a result of programmatic improvements in Serbia and support of the Global Fund to fight AIDS, TB and malaria since 2005 when TB laboratory diagnostic capacities were expanded that provided an opportunity to improve both diagnosis and surveillance in the country [12]. In our study, there was no notified HIV-positive case among children and adolescents; the rate was lower than in EU/EEA countries [2]. Despite there was significant increase in HIV testing over the time in Serbia, the proportion of TB cases with known HIV status is still very low compared to EU/EEA countries [2], since there is no routine offering of HIV testing for TB patients [24]. BCG vaccination coverage in our study was higher than globally [25] and in the EU/EEA countries implementing national BCG vaccination policy for all [26]. In Serbia, BCG vaccine is mandatory and administered to newborn children as a single dose [27]. While most experts agree that BCG is efficacious against severe forms of childhood TB, little is known about how long the BCG vaccine protects against TB. A new scientific insight from Norway suggests that vaccine could be more cost effective than has been previously estimated [28].

The TB treatment success rate among child and adolescent population in Serbia was higher than the EU/EEA treatment success rate [2] at the level of the global target [1] due to decrease of patients lost to follow up and low mortality. The progress made during the study period could be the result of the continuous efforts invested in capacity building of the health professionals for diagnosis, treatment and follow up of the patients.

We identified new TB, male sex, PTB and comorbidities and as independent factors associated of treatment success, while age below 5 years and social vulnerability as independent factors associated with unsuccessful treatment among child and adolescent TB cases.

Many studies reported retreatment as a predictor of negative treatment outcomes [29,4]. One of the fundamental strategies in TB control is early case detection, rapid initiation of adequate treatment, treatment adherence and prevention of disease recurrence, in order to achieve treatment success and avoid toxic effects of re-treatment cycles [30].

We identified male sex as independent predictor of treatment success. In the last two decades, very few studies analyzed trends and treatment outcomes in childhood TB considering the gender of the patients [31,32]. Since the majority of our patients were adolescents and having in mind there studies, findings may suggest a role of hormones, as initial difference in male and female TB trends and treatment outcomes after puberty is observed, due to role of androgens and estrogens in modulating immune system synthesis of pro-inflammatory and immunosuppressive cytokines, as well as antibody production [32,33]. Gender should be further considered not only from an epidemiological point of view but also from a clinical one, being an important factor in the pathogenesis, management and prognosis of this infection [33].

In our study PTB and comorbidities were identified as factors associated with treatment success. Other studies identified comorbidities [31,4] and HIV positivity [32] as factors associated with unsuccessful treatment due to increased mortality. The reason might be the fact that patients with infectious forms of PTB and comorbidities are likely to be hospitalized and under direct supervision of the health worker, unlikely to be lost to follow up. On the other hand, EPTB forms of the disease in children are often severe, towards unfavorable treatment outcomes [23,24].

We find that age below 5 year was an independent predictor of negative treatment outcome, consistent with other studies [34,35]. In children under 5 years of age, primary TB infection frequently progresses to severe forms of the disease. Development of fatal miliary TB or meningeal TB is a significant concern. Osteoporosis, sclerosis, and bone involvement are more common in children with TB than in adults with the disease. The epiphyseal bones can be involved because of their high vascularity [35,36]. Effective early
intervention in this age group would have the potential to reduce the mortality [37].

Furthermore, we identified social vulnerability as a factor associated with negative TB treatment outcomes. People living in unfavorable circumstances have worse health at all ages. The linkage between TB and poverty has long been noted but studies have only recently been undertaken to identify socioeconomic burden of TB. Increased probability of becoming infected with TB, developing active TB and poor adherence to treatment are associated with malnutrition, crowding, poor air circulation, and poor sanitation - all associated with poverty [38]. Social vulnerability is often connected to perception of stigma. Many studies have identified bad cooperation and communication with the health service due to stigma, resulting in delays in medical care, affecting adherence to treatment leading to interruptions, prolonged treatment and drug resistance [39,40]. These circumstances have public health implications in ongoing disease transmission and the risk of drug resistance in the community [39].

Data related to latent tuberculosis infection (LTBI) and chemoprophylaxis were not available for the study period since national Law on population protection against infectious diseases recommends recording and reporting on TB disease, not TB infection. In addition, data on cases from contacts were missing for two thirds of the cases. Despite its limitations, this study is the first in-depth analysis of childhood TB epidemiology in Serbia and provides evidence on the risk factors associated with treatment outcomes.

Conclusions

In the period 2005-2016, stable trend of tuberculosis is notified in child and adolescent population. Although case detection, bacteriological confirmation, drug susceptibility testing and HIV testing among child and adolescent population are improved in Serbia, the values are still below the global targets. During the study period, treatment success rate remain the same. To further improve TB treatment outcomes, it is important to focus on female, age group 5-18, EPTB, and socially vulnerable groups.

Acknowledgements

The authors gratefully acknowledge Dr Goranka Loncarevic and Dr Milena Kanazir for providing the data on BCG vaccination coverage used in the analysis.

Authors’ Contributions

Concept and design (MS), statistical analysis (MS), interpretation of the data (MS, LS, DS, TAV) drafting the manuscript (MS) and critical revision of the manuscript for important intellectual content (MS, LS, DS, VJ, VR, TAV).

References

1. World Health Organization (2019) Global tuberculosis report 2018. Geneva: WHO report. Available: https://www.who.int/tb/publications/global_report/en/. Accessed 12 September 2020.
2. European Centre for Disease Prevention and Control (ECDC) (2020) Tuberculosis surveillance and monitoring in Europe, 2018. Stockholm: ECDC report. Available: https://www.ecdc.europa.eu/en/publications-data/tuberculosis-surveillance-and-monitoring-europe-2020-2018-data. Accessed 12 September 2020.
3. Jenkins HE (2016) Global Burden of Childhood Tuberculosis. Pneumonia (Nathan) 8: 24.
4. Hamid M, Brooks MB, Madhani F, Ali H, Naseer MJ Childhood Tuberculosis Karachi Group, Beearrera M, Amanullah F (2019) Risk factors for unsuccessful tuberculosis treatment outcomes in children. PLoS One 14: e0222776.
5. Carvalho ACC, Cardoso CAA, Martire TM, Migliori GB, Sant’Anna CC (2018) Epidemiological aspects, clinical manifestations, and prevention of pediatric tuberculosis from the perspective of the End TB Strategy. J Bras Pneumol 44: 134-144.
6. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B (2008) Pediatric tuberculosis. Lancet Infect Dis 8: 498–510.
7. Seddon JA, Shingadia D (2014) Epidemiology and disease burden of tuberculosis in children: a global perspective. Infect Drug Resist 7: 153–65.
8. Ogbeude CL, Adepoju V, Ekerete-Udofia, Ekerete-Udofia C, Abu E, Egesema G, Chukwueme N, Gidado M (2018) Childhood Tuberculosis in Nigeria Disease: Presentation and Treatment Outcomes. Health Serv Insights 11: 117863918757490.
9. Tilahun G, Gebre-Selassie S (2016) Treatment outcomes of childhood tuberculosis in Addis Ababa: a five-year retrospective analysis. BMC Public Health 16: 612.
10. Aw B, Ade S, Hinderaker SG, Dlamini N, Takarinda KC, Chiaa K, Feil A, Traoré A, Reid T (2017) Childhood tuberculosis in Mauritania, 2010–2015: diagnosis and outcomes in Nouakchott and the rest of the country. Public Health Action 7: 199–205.
11. Stosic M, Grujicic SS, Grgurevic A, Kuruc V, Ristic L, Antonijevic G, Jevtic M, Plavsa D, Vukicevic TA (2020) Trends in tuberculosis notification and mortality and factors associated with treatment outcomes in Serbia, 2005 to 2015. Euro Surveill 25: 1900322.
12. Gledovic Z, Grgurevic A, Pekmezovic T (2006) Childhood tuberculosis in Serbia. Pediatr Infect Dis J 25: 269-70.
13. Sandgren A, Hollo V, Quinten C, Manissero D (2011) Childhood tuberculosis in the European Union/European Economic Area, 2000 to 2009. Euro Surveill: 16: 19825.
14. World Health Organization (2014) Standards and benchmarks for tuberculosis surveillance and vital registration systems. Checklist and user guide. Geneva. Available: https://www.who.int/tb/publications/standardsandbenchmarks/en/. Accessed 15 September 2020.
15. World Health Organization (2014) Definitions and reporting framework for tuberculosis – 2013 revision. Geneva. Available: https://apps.who.int/iris/ handle/10665/79199. Accessed 15 September 2020.
16. Radosavljevic Asic G, Rebic P, Kuruc V (2009) Methodological guidelines for tuberculosis prevention and control. Belgrade: Ministry of Health of the Republic of Serbia. Available: http://www.batut.org.rs/download/izdvajamo/tuberkuloza/Revidirano%20Strucno-metodolosko%20putstvo%20sprecanavanje%20uzbijanje%20TB%20RS%202009.pdf Accessed: 16 September 2020. [Article in Serbian]

17. Savić B, Vuković D, Dakić I, Aranđelović I (2015) Guidelines for microbiological diagnosis of tuberculosis. 3rd ed. Belgrade: Ministry of Health of the Republic of Serbia. Available: http://www.batut.org.rs/download/izdvajamo/tuberkuloza/Video%20Za%20Mikrobiologulu%20Dijagnostiku%20TB.pdf. Accessed on 16 September 2020. [Article in Serbian]

18. Holmes CB, Hausler H, Nunn P (1998) A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis 2: 96–104.

19. World Health Organization (2014) Standards and benchmarks for tuberculosis surveillance and vital registration systems: checklist and user guide. Geneva. Available at: https://www.who.int/tb/publications/standardsandbenchmarks/en/. Accessed 16 September 2020.

20. Marais BJ, Gie RB, Schaaf HS, Hesseling AC, Obihara CC, Nelson LJ, Enarson DA, Donald PR, Beyers N (2004) The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis: 8: 278–285.

21. Morabia A (2014) Snippets from the past: cohort analysis of disease rates – another piece in a seemingly still incomplete puzzle. Am J Epidemiol: 180: 189–196.

22. Groschel MI, van den Boom M, Migliorini GB, Dara M (2019) Prioritizing children and adolescents in the tuberculosis response of the WHO European Region. Eur Respir Rev: 28: 180106.

23. Stošić MB, Simić DM, Babić DD, Ristić L, Kuruc V (2019) HIV prevalence, knowledge and self-perceived risk of HIV infection among tuberculosis patients in Serbia. Cent Eur J Public Health 27: 99–104.

24. Oliwa JN, Karumbi JM, Marais BJ, Gie RB, Madhi SA, Graham SM (2015) Tuberculosis as a cause or comorbidity of childhood pneumonia in tuberculosis-endemic areas: a systematic review. Lancet Respir Med 3: 235–243.

25. Mulongeni P, Hermans S, Caldeway J, Bekker LG, Wood R, Kaplan R (2019) HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. PLoS One: 14: e0210937.

26. World Health Organization (2018) Roadmap towards ending TB in children and adolescents. Geneva. Available: https://apps.who.int/iris/bitstream/handle/10665/275422/9789241514798-eng.pdf?ua=1. Accessed on 16 September 2020.

27. Infuso A, Falzon D, EuroTB network (2006) European survey of BCG vaccination policies and surveillance in children, 2005. Euro Surveill: 11: 6-11.

28. Ministry of Health of the Republic of Serbia (2018) Rulebook on immunization and medicinal protection (Official Gazette of the Republic of Serbia 88/2017, 11/2018 and 14/2018) Available: https://www.paragraf.rs/propisi/pravilnik_o_imunizaciji_i_na_cinu_zastite_lekovima.html Accessed: 16 September 2020. [Report in Serbian]

29. Nguipod-Djomo P, Heldal E, Rodrigues LC, Abubakar I, Mangtani P (2016) Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect Dis 16: 219–226.

30. Ohene SA, Fordah S, Dela Boni P (2019) Childhood tuberculosis and treatment outcomes in Accra: a retrospective analysis. BMC Infect Dis 19: 749.

31. World Health Organization (2014) Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd Ed. Geneva. Available: https://www.who.int/tb/publications/childtb_guidelines/en/. Accessed 16 September 2020.

32. Syридou G, Mavrikou M, Amanatidou V, Spyridis N, Prasad P, Papaventis D, Kanavakis, Zaatish T, Tselinb MN (2012) Trends in the epidemiology of childhood tuberculosis in Greece. Int J Tuberc Lung Dis 16: 749–755.

33. Abubakar I, Laundy MT, French CE, Shingadia D (2008) Epidemiology and treatment outcome of childhood tuberculosis in England and Wales: 1999–2006. Arch Dis Child: 93: 1017–1021.

34. Sital A, Chiappini E, Montagnani C, Orlandini E, Buzzoni C, Galli L, de Martino M (2014) Sexual dimorphism in tuberculosis incidence: children cases compared to adult cases in Tuscany from 1997 to 2011. PLoS One 9: e105277.

35. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B (2008) Paediatric tuberculosis. Lancet Infect Dis 8: 498–510.

36. International Union against Tuberculosis and Lung Diseases (2016) The Union’s desk guide for diagnosis and management of TB in children. 3rd edition. Paris. Available: http://www.tbonline.info/media/uploads/documents/2016_des k_guide_3rd_web.pdf. Accessed 16 September 2020.

37. Luzzato R, Migliorini GB, Zignolo M, Cirillo DM, Maschio M, Tominz R, Ventura G, Patussi V, D’Ambrosio L, Centis R, Michieletto F, Trovato A, Salton F, Busetti M, Di Santolo M, Raviglione M, Conflonier I, Muzzoni G (2011) Children under 5 years are at risk for tuberculosis after occasional contact with infectious patients: outpatient from a smear positive healthcare worker. Eur Respir J 50: 1701414.

38. Waaler HT (1982) Tuberculosis and socio-economic development. Bull Int Union Tuberc 57: 202–205.

39. World Health Organization (2001) A human rights approach to tuberculosis. Available: https://apps.who.int/iris/bitstream/handle/10665/66701/WHO _CDS_STB_2001.9.pdf?sequence=1&isAllowed=y. Accessed 16 September 2020.

Corresponding author
Maja Stosic, MD, PhD
Public Health Institute of Serbia “Dr Milan Jovanovic Batut”
Dr Subotica 5, 11000 Belgrade, Serbia
Phone number: +381 11 2434642
E-mail: maja_stosic@batut.org.rs

Conflict of interests: No conflict of interests is declared.